TEL AVIV, Israel, Jan. 19, 2021 /PRNewswire/ -- Galmed
Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a
clinical-stage biopharmaceutical company for liver, metabolic and
inflammatory diseases, announced today that it will host a Key
Opinion Leader (KOL) symposium and pipeline update on Tuesday, January 26, 2021 at 11am Eastern Time. The symposium will
primarily focus on Aramchol, currently in Phase 3 for non-alcoholic
steatohepatitis (NASH) and liver fibrosis, and Amilo-5MER for
chronic inflammatory disorders.
The symposium will feature KOL Arun Sanyal, MD of Virginia Commonwealth University Medical Center,
and Shomron Ben-Horin, MD of Tel-Aviv
University. The event will provide a detailed overview of
Galmed's two pipeline assets, Aramchol in Phase 3 for NASH and
fibrosis and Amilo-5MER in development for chronic inflammatory
disorders. A Q&A session will follow the formal
presentations.
To register for the event, please click here.
If you are unable to attend the event live, a replay will be
available on the Galmed website following the event for a limited
time.
Arun Sanyal, MD is Professor of
Medicine and Chairman of the Gastroenterology Division of
Virginia Commonwealth University (VCU)
Medical Center in Richmond,
Virginia, USA. Prof. Sanyal also serves as Chairman of the
National Institutes of Health (NIH) non-alcoholic steatohepatitis
(NASH) Clinical Research Network and the Liver Forum for NASH and
fibrosis.
Professor Sanyal's research interests include all aspects of
non-alcoholic fatty liver disease and NASH as well as complications
of end-stage liver disease. He has served as a member of numerous
advisory boards to pharmaceutical companies and the liver center at
Yale University. He chaired the
hepatobiliary pathophysiology study section of the NIH and was a
founding member of the Hepatology Committee of the American Board
of Internal Medicine. He has also served as Secretary and President
of the American Association for Study of Liver Diseases. Prof.
Sanyal is a leading global expert and clinician in chronic liver
disease.
Prof. Sanyal is a leader in training future medical researchers and
in identifying the mechanisms and clinical outcomes and developing
effective management for nonalcoholic fatty liver disease and
metabolic syndrome. Professor Sanyal has developed, mediated, and
encouraged global liver research as a physician-scientist for over
25 years.
Professor Ben-Horin specializes in inflammatory bowel diseases
(IBD) and has received his medical and gastroenterology training in
Israel and was a Post-Doc
scientist in immunology at Columbia
University Presbyterian Hospital in New-York, USA. Prof. Ben-Horin is presently
the Chief of the Gastroenterology Department at Sheba Medical
Center, Israel, a Full Professor
of Medicine at the Tel-Aviv University,
and an Adjunct Professor of Medicine at the Sun Yat-Sen University
Hospital, Guangzhou, China. He has
served as a member of the Scientific Committee of the European
Crohn's and Colitis Organization (ECCO) and is presently the
Chair of the Israeli IBD Society. Prof. Ben-Horin has published
over 200 peer-reviewed scientific papers and is a member of the
Editorial Board of the journals Gut, APT and JCC. Prof. Ben-Horin
is also the Director of IBD-passport: A web-based global support
program for traveling IBD patients.
About Aramchol and Non-alcoholic Steatohepatitis
(NASH)
Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid
bile acid conjugate, liver targeted SCD1 modulator, developed as an
oral therapy for the treatment of nonalcoholic steatohepatitis
("NASH") and fibrosis. Aramchol's ability to modulate hepatic lipid
metabolism was discovered and validated in animal models,
demonstrating downregulation of the three key pathologies of NASH:
steatosis, inflammation and fibrosis. The effect of Aramchol on
fibrosis is mediated by downregulation of steatosis and directly on
human collagen producing cells. Aramchol has been granted Fast
Track Designation status by the FDA for the treatment of NASH.
NASH is an emerging world crisis impacting an estimated 3% to 5%
of the U.S. population and an estimated 2% to 4% globally. It is
the fastest growing cause of liver cancer and liver transplant in
the U.S. due to the rise in obesity. NASH is the progressive form
of non-alcoholic fatty liver disease that can lead to
cardiovascular disease, cirrhosis and liver-related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. is a clinical stage drug development
biopharmaceutical company for liver, metabolic and inflammatory
diseases. Our lead compound, Aramchol™, a backbone drug candidate
for the treatment of NASH and fibrosis is currently in a Phase 3
registrational study. We are also collaborating with the
Hebrew University in the development of
Amilo-5MER, a 5 amino acid synthetic peptide and plan to initiate a
first in human study by the first quarter of 2021.
Forward-Looking Statements
This press release may include forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to Galmed's objectives, plans and strategies,
as well as statements, other than historical facts, that address
activities, events or developments that Galmed intends, expects,
projects, believes or anticipates will or may occur in the future.
These statements are often characterized by terminology such as
"believes," "hopes," "may," "anticipates," "should," "intends,"
"plans," "will," "expects," "estimates," "projects," "positioned,"
"strategy" and similar expressions and are based on assumptions and
assessments made in light of management's experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Many factors could cause Galmed's actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to, the following: the timing and cost of Galmed's
pivotal Phase 3 ARMOR trial, or the ARMOR Study or any other
pre-clinical or clinical trials; completion and receiving favorable
results of the ARMOR Study for Aramchol or any other pre-clinical
or clinical trial; the impact of the COVID-19 pandemic; regulatory
action with respect to Aramchol or any other product candidate by
the FDA or the EMA; the commercial launch and future sales of
Aramchol or any other future products or product candidates;
Galmed's ability to comply with all applicable post-market
regulatory requirements for Aramchol or any other product candidate
in the countries in which it seeks to market the product; Galmed's
ability to achieve favorable pricing for Aramchol or any other
product candidate; Galmed's expectations regarding the commercial
market for NASH patients or any other indication; third-party payor
reimbursement for Aramchol or any other product candidate; Galmed's
estimates regarding anticipated capital requirements and Galmed's
needs for additional financing; market adoption of Aramchol or any
other product candidate by physicians and patients; the timing,
cost or other aspects of the commercial launch of Aramchol or any
other product candidate; the development and approval of the use of
Aramchol or any other product candidate for additional indications
or in combination therapy; and Galmed's expectations regarding
licensing, acquisitions and strategic operations. More detailed
information about the risks and uncertainties affecting Galmed is
contained under the heading "Risk Factors" included in Galmed's
most recent Annual Report on Form 20-F filed with the SEC on
March 12, 2020, and in other filings
that Galmed has made and may make with the SEC in the future. The
forward-looking statements contained in this press release are made
as of the date of this press release and reflect Galmed's current
views with respect to future events, and Galmed does not undertake
and specifically disclaims any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Logo -
https://mma.prnewswire.com/media/595923/Galmed_Pharmaceuticals_Ltd_Logo.jpg
View original content to download
multimedia:http://www.prnewswire.com/news-releases/galmed-hosting-kol-symposium-and-pipeline-update-301210736.html
SOURCE Galmed Pharmaceuticals Ltd.